

---

# INDEX

**Note:** Page numbers in *italics* denote figures, tables, or photographs on the corresponding page.

## A

- Abel, Frederick, 52  
access  
    federally funded research in U.S., 116  
    green open, 115–117  
    online publication, 110, 113,  
        115–120, 122–123  
    open access, 113, 115–120, 122–123  
    to paper in review process, 120  
    paywalls, 112  
ACLU (American Civil Liberties Union), 50  
acquired characteristics, 245  
adenovirus, 201  
Adler, Reid, 46  
adrenaline, 40, 53–54  
adult T-cell leukemia virus (ATLV), 190  
*A for Andromeda*, 266–267  
*agouti* gene, 254, 254  
AIDS, 156–158, 190, 255  
Albert Einstein College, 250  
 $\alpha$ -helix, 172, 273  
AlphaFold, 19–22, 20  
Altman, Sidney, 198  
Alzheimer's, 197  
American Civil Liberties Union (ACLU), 50  
American Society for Microbiology, 99  
Amgen, 81  
Anderson, Chris, 17  
Anderson, Philip, 269  
Angell, Narcia, 103  
annotation, 228  
antibiotic resistance gene, 41, 42, 151  
APC (Article Publishing Charge), 117–118  
Applied Biosystems, 47, 227  
applied research/science, 24–25, 53, 54,  
    59–60, 62, 158  
*Arabian Journal of Geosciences*, 100  
*Arabidopsis thaliana*, 246, 246–247,  
    251, 273  
Arber, Werner, 212–213  
Arnold, Matthew, 6  
Article Publishing Charge (APC), 117–118  
artificial intelligence (AI), 10  
    big data, 18–19  
    examination of submitted papers, 145  
    modeling biological phenomena, 22  
    protein structure, 19–21, 20  
    use in scientific publishing, 100  
arXiv system, 110–111  
Asilomar meetings, 150–151, 153, 155, 156  
assumptions, danger of, 73–74  
Astbury, William, 174–175  
ATLV (adult T-cell leukemia virus), 190  
attitude, scientific, 7–8, 9, 23, 29, 78  
auditing, 137–139  
authorship  
    asterisks and footnotes, 75  
    CRediT, 27  
    honorary, 75  
    Jacob on process of, 66  
    number of authors, 34, 35, 75, 78, 87–88,  
        88, 139, 140, 180, 209  
    on patents, 56  
    paying to publish by authors, 116–118  
    responsibility in, 26–27  
    senior author, 75, 178–179, 187, 227  
autosomes, 210–211, 217, 273  
Avery, Oswald, 167, 178
- ## B
- Babbage, Charles, 136–137  
Bacon, Francis, 22, 24

## 312 INDEX

- bacteriophage, 167–169, 169, 204, 212, 237, 273
- Baltimore, David, 27–28, 186–187
- Banbury Center of Cold Spring Harbor, 61
- banding, chromosome, 215, 216–217
- Banfield, Jillian, 238
- Bang, Oluf, 189
- Barrangou, Rodolphe, 239
- base pairs, 176, 177, 268, 273
- basic research, 25, 42, 53–54, 59–60, 66, 134, 158–159
- Bayer, 81
- Bayh–Dole Act (1980), 43
- Beighton, Elwyn, 174
- beliefs, triumph of data over mistaken, 11
- Bell, Florence, 174
- Berg, Paul, 46, 150–152, 156–157
- Berget, Susan, 201
- Bermuda Principles, 33, 84, 85
- Big Bang theory, 270
- big data, 15
- artificial intelligence (AI), 18–19
  - assessment of, 17
  - correlations, 32, 36–37
  - Google Flu Trends, 32
  - human genome sequence, 37
  - omics, 36
  - physics, 18
- Big Data* (Mayer-Schönberger and Cukier), 17–18
- Big Pharma
- corruption of medicine, 34
  - opinion of academics on, 53
  - patent strategy, 60
  - secrecy, reliance on, 58, 60
- big science, 9, 15
- authorship, 27
  - correlations, 17–18, 28–29
  - gap between original data and interpretation, 231
  - genome sequencing, 215–216
  - retractions, frequency of, 139–140
  - specialization, 26
- Bik, Elisabeth, 145
- Biochemica et Biophysica Acta* (BBA), 90
- Biogen, 55, 57, 60, 201, 216
- biology
- citation frequency of papers, 92–93
  - discoveries in, 265–266, 266
  - disdain for commercial applications, 53
  - intrinsic variability of living organisms, 8
  - number of authors on scientific papers, 34, 35
  - physics compared to, 8–9, 265, 266, 267–271
  - quality control in, 267
  - U.S. government funding for research, 128
- BioMed Central, 113
- bioRxiv server, 111
- biotechnology, 53–62
- academia's relationship with, 53–62
  - patent and publish model, 58, 60
  - publication by press conference, 104
- Biozentrum, 212
- Bird, Adrian, 249, 252
- Bishop, Mike, 189–190
- blending, 166, 169, 193
- Bohr, Niels, 206, 243
- Botstein, David, 36, 77, 212–213, 216–217
- Boyer, Herb, 41–43, 53, 55–56
- Boyle, Robert, 89
- Boyle's Law, 89
- Bragg, Lawrence, 172, 178
- branches of science, 5
- BRCA1* and *BRCA2*, 49–50
- Brenner, Sydney, 72
- Broad Institute, 156
- Broker, Tom, 201
- Brown, Pat, 113
- Brownian motion, 18
- bureaucracy, university, 131
- Bush, Vannevar, 158–159
- Butterworth-Springer, 90
- ### C
- Caenorhabditis elegans*, 255, 273
- Cairns, John, 189
- Caltech, 172
- Cambridge, 171–172, 173, 177–178, 181, 223, 257
- cancer, virus-associated, 185, 188–191
- Capecchi, Mario, 130
- Carnegie Institute, 169, 253
- cas* genes, 235–237, 273
- Caskey, Tom, 219
- CASP (Critical Assessment of Structure Prediction), 19

- Cas1 protein, 239  
Cas9 protein, 237–238, 240–241  
catalysis, RNA, 198, 198–200  
Cavendish Laboratory, 171–172, 173  
CCR5 gene, 156  
cDNA, 50, 51, 57  
Cech, Tom, 28, 198–200  
Celera, 47, 84–85, 227–228, 231  
*Cell*, 3, 25, 36  
    associated journals, 98  
    as brand, 99  
    changes after acceptance, 71  
    changing conclusions of paper, 107–108  
    competing papers, 72  
    cost to start, 118  
    CRISPR paper rejection, 237  
    editorial decision process, 96  
    Elsevier purchase of, 98  
    external review of papers, 71–72  
    first issue, 118  
    fraud detection, 141–143, 145–146  
    frequency of fraud, 141  
    in hierarchy of scientific journals, 91,  
        94–96, 97  
    impact factor, 94, 114  
    infectious protein papers, 194, 196–197  
    influence of, 114  
    Ingelfinger rule, 102  
    judging papers on data, 68, 74  
    Lander article, 156  
    online publication, 110  
    order of authors, 75  
    page charge, 117  
    paywalls, 112  
    press reporting of papers in, 153  
    rejection of papers, 92, 96  
    Reproducibility Project, 80  
    retractions, 84  
    review of “Atlas of Science,” 104  
    signed reviews, 73  
    speed of publication, 88–89, 103, 120,  
        240  
    splicing papers, 202, 203  
    test for editor applicants, 33  
    typeface and section placement, 91  
    unique materials, availability of, 83  
cell, creation from DNA sequence, 267, 270  
cell lines, 61, 83, 260  
Cell Press, 98, 100, 114, 120–121  
censorship, 77  
Central Dogma, 183–186, 184, 185, 191,  
    197, 244  
Cetus, 54–55  
Chakrabarty, Ananda, 40–41, 45  
chaperones, 196  
Chargaff, Erwin, 175  
Charpentier, Emmanuelle, 156–157,  
    237–239  
Chase, Martha, 169  
chimpanzees, 229–230  
Chow, Louise, 201  
chromosomes  
    autosomes, 210–211, 217, 273  
    banding, 215, 216–217  
    definitions, 273  
    genes residing upon, 164  
    linkage map, 211, 211–213, 215  
    number in human genome, 210–211  
    sex, 210–211, 277  
Church, George, 239–240  
Churchill, Winston, 72–73  
citation analysis, 27, 93, 94, 97, 101, 105,  
    108, 114  
citations  
    in Atlas of Science, 104  
    frequency of papers in biology, 92–93  
    hierarchy of journals by number of, 96,  
        97, 105  
    of highly cited papers, 97  
    impact factor compared to number of,  
        94, 96  
    importance measured by, 93–94  
    of method papers, 94  
    in online journals, 96  
    of preprint, 111  
    of retracted papers, 139  
    uncited papers, 100, 122  
    of work funded by NIH, 93  
City of Hope, 55  
clinical trials, failure of, 81  
cloning  
    animals, 154–155, 259  
    DNA, 40–42, 41, 72, 79, 83, 149–150, 157  
    human, 154, 259  
    reproductive, 259  
    shotgun, 226–227, 277  
    therapeutic, 260  
cloning vector, 40

- clustered regularly interspaced short palindromic repeats. *See* CRISPR
  - Cohen, Stan, 41–43, 55, 150
  - cold fusion, 82, 103, 105
  - Cold Spring Harbor Laboratory, 111, 150, 188, 188–189, 201, 203, 222–223
  - Cold Spring Harbor Symposium, 102, 186, 188, 188, 216, 222
  - Coleridge, Samuel Taylor, 22
  - Columbia University, 175
  - commercial applications, 53, 58–59, 62
  - common cold, 153
  - communality, 4
  - competition
    - CRISPR, 238–241
    - DNA structure discovery, 171–181
    - early biotech companies, 60–61
    - gene editing, 238–241
    - as intrinsic part of science, 179–180
    - Nobel Prize, 106
    - priority disputes, 52
    - rapid publication, 186–187
    - review of scientific paper, 70–72
    - scientific journals, 95
    - selection of data, 136
  - computers, increase in power of, 9–10
  - confidence level, 82–83
  - conflict of interest, 4, 77
  - consciousness, 205, 271–272
  - constructivism, 24
  - containment facilities, 151–152
  - contracts, 26
  - controlled experiment, 8
  - controls
    - data validity, 15
    - in question-driven science, 17
  - cooking, 137
  - correlations
    - among genome sequence patterns, 37
    - big data/big science, 17–18, 28–29, 32, 36–37
    - cause and effect, 249
    - suspicion of, 17
  - Council of Advisors on Science and Technology, 156
  - Council of the American Society for Biochemistry and Molecular Biology, 132
  - COVID, 37, 77, 103, 152–154, 225, 255
  - CpG islands, 230, 252, 273
  - CRedit (Contributor Roles Taxonomy), 27
  - Crick, Francis
    - birth anniversary, 3
    - Central Dogma, 183, 186
    - consciousness, 271
    - criticism of amateurs, 73–74
    - on discovery of splicing, 204
    - DNA structure, 171, 173–181, 175, 209
    - on dogma, 183
    - Nobel Prize, 106, 178
    - panspermia, directed, 266
    - on physics and chemistry, 265
    - What Mad Pursuit*, 173–174
  - Crick Institute, 181
  - CRISPR, 10, 233–242, 273
    - artificial, 237
    - base-pairing, 176
    - competition, 238–241
    - discovery of, 101, 234
    - ethical issues, 155–156
    - guide RNA, 237–238, 240–241
    - Nobel Prize, 156
    - papers published, 236–241, 240
    - papers rejected, 235, 237–238
    - patents, 47, 233, 236, 241
    - power of technique, 155
    - specificity of the system, 236–237
  - criticism in science, 70, 72–74, 76, 119
  - crystallography, 19–21, 171–172, 174, 176–177
  - culture, scientific, 3, 5–7, 23
  - Current Contents*, 93, 122
- D**
- Danisco, 236–237
  - Darwin, Charles, 270
  - data
    - duplication of, 137–139
    - fabrication, 137–138
    - fudging, 137, 165–166
    - ownership of, 173
    - selection, 135–137, 140, 143, 166
    - theory trumped by, 28
    - triumph of, 5, 11, 52, 256, 265
    - viewed with skepticism, 145
  - database
    - data mining, 33, 36
    - Lander’s defense of, 241–242

- MEDLINE, 93
- PDB, 86, 276
  - as primary source, 33, 84–86
  - PubMed, 87, 92, 111, 115, 138, 276
  - Retraction Watch, 138–139
- data-driven science, 17–18, 29, 31, 36, 93, 177
- data mining, 17, 31–37
- Davis, Ron, 149–150
- Dean, Caroline, 248, 256
- deduction, 15, 22, 185
- DeepMind, 19–20
- Delbrück, Max, 135, 144, 204
- demethylases, 252
- Denisovans, 231
- Department of Energy (DOE), 218
- Dewar, James, 52
- Difference Engine, 136
- discovery
  - appreciation and integration into canon, 164
  - effect on science, 50–51
  - likelihood as proportional to time at the bench, 131
  - misrepresentation of sequence of, 128
  - pace of, 9–10
  - priority, 51–52
  - researchers as entrepreneurs, 54
  - scientific paper as related to, 65–66
  - simultaneous, 51–52
  - technique driving, 209
- discovery science, 25, 36
- disinterestedness, 4
- DNA
  - A-form and B-form, 173
  - Avery experiments, 167, 178
  - bacteriophage, 167–169, 169
  - base-pairing, 176, 177, 268
  - Central Dogma, 183–186, 184, 185, 191
  - cloning, 40–42, 41
  - definition, 273
  - double helix, 173, 175–177, 176, 178–181, 210, 251, 266
    - as genetic material, 167–170, 194, 210–211
  - Hershey–Chase experiments, 169
  - information in, 210
  - Meselson–Stahl experiment, 179
  - model, 175, 176, 179
  - Neanderthal, 37, 230, 321
  - plasmids, 42, 150–151, 276
  - replication, 268
  - structure, 171–181, 209, 268
  - synthetic, 57
  - thread of life, 10
  - transcription into RNA, 184–187
  - unifying force in modern biology, 11
- DNA fingerprinting, 213–215, 214, 221, 274
- DNA polymerase, 223
- DNA sequence
  - cell creation from, 267, 270
  - patents, 40, 45–51, 48, 51
  - release to public databases, 33, 48, 84–85, 85
- DNA sequencers, 224, 227
- DNA sequencing
  - automated center, 226
  - cost and speed, 224–225, 225
  - defined, 274
  - early history, 223–224, 224
  - human genome sequencing, 215–219, 221–231
  - large-scale, 209–210
  - next-generation, 224, 276
  - Nobel Prize, 216
  - read-length, 224–225
  - shotgun, 226–227
  - spin-offs, unanticipated, 225
- doctrines, 193–206
- DOE (Department of Energy), 218
- dogma, 183–192
  - Central Dogma, 183–186, 184, 185, 191, 197, 244
  - dogmatic phase of molecular biology, 205
  - epigenetics contradiction of, 247–249
  - as impediment to progress, 256
  - nucleic acid as the genetic material, 193
  - nucleotides in DNA, 251
  - prion behavior, 195
  - reactions catalyzed by enzymes, 199
  - rejection of papers conflicting with, 91–92
  - threat when theory becomes, 204
  - timeline of twentieth century, 196
  - time required to overthrow, 191
- Dolly the sheep, 154–155, 259, 260
- Donohue, Jerry, 181

## 316 INDEX

Doolittle, Russ, 33  
double helix structure, 173, 175–177, 176,  
178–181, 210, 251, 266  
*The Double Helix* (Watson), 67, 172–173  
Doudna, Jennifer, 156, 237–240  
*Dreams of a Final Theory* (Weinberg), 9  
Dutch Famine, 254

### E

e-BioMed, 110, 113, 274  
economics, reproducibility problem in,  
81–82  
*The Economist*, 153  
Eddington, Arthur, 200  
Edman method, 223  
educational system, 6–7  
Einstein, Albert, 69–70, 200  
Eisen, Michael, 113, 118  
electronic publication, 109–124  
electrophoresis, 213, 274  
*eLife*, 96, 97, 118–119, 239  
Ellermann, Vilhelm, 189  
Elsevier, 90, 97–98, 100, 112, 114, 121  
*EMBO Journal*, 117  
emergence, 269–271  
ENCODE database (Encyclopedia of DNA  
Elements), 36, 274  
enzymes  
dogmas of, 196  
reaction catalysis, 198  
restriction, 212–214, 219, 233, 235–236  
ribozymes, 198, 198–200  
epidemiology, 32  
epigenetic marks, 249, 253, 260  
epigenetics, 10, 205, 243–256, 266, 268  
definitions of, 248–249, 249, 274  
Dutch Famine, 254  
*FLC (FLOWERING LOCUS C)*, 246–249,  
247, 251  
imprinting, 251–254  
incomplete knowledge of, 255–256  
in maize, 253  
methylation, 37, 249, 251–254, 256  
in mice, 253–254, 254  
number of papers on, 249  
social, 244  
terminology, 253  
transgenerational inheritance, 255  
X-inactivation, 250–251, 277

Errington, Tim, 80  
ES (embryonic stem) cell, 260–262, 274  
*Escherichia coli*, 42, 56, 150, 234, 237, 274  
e-science, 109–124  
ethics, 149–159  
CRISPR, 10  
germline editing, 155–157  
human cloning, 259  
stem cells, 257, 261  
European Molecular Biology Organization,  
117  
evolution, 229, 247, 270  
exon, 51, 201, 274  
Experimental Procedures, 68, 91  
experimental science, controls as feature  
of, 8, 17  
expressed sequence tags (ESTs), 46

### F

fabrication, 137–138  
faking data, 137, 140, 142–143  
falsification, 137  
feline leukemia virus, 189  
Feynman, Richard, 23  
fingerprinting, DNA, 213–215, 214, 221,  
274  
Fisher, H.A., 165  
*FLC (FLOWERING LOCUS C)*, 246–249,  
247, 251  
Fleischmann, Martin, 82  
folding, protein, 195–196  
forgery, 136, 142–143  
Franklin, Rosalind, 171, 173, 176–178, 180  
fraud, 135–148  
auditing, 137–138, 137–139  
congressional investigation of, 186  
continuum of behavior, 137  
dealing with, 145–146  
defense to accusation of, 143  
detection of, 137–138, 141–147  
duplication of data, 137–139  
fabrication, 137–138  
faking data, 137, 140, 142–143  
habitual, 143  
intuitive approximation, 22  
presumption of innocence, 140  
prominent cases, 147  
reactions/response to, 144–145, 147–148  
retractions, 138–147, 140

- scientific paper as, 65
- as solitary affair, 139–140
- susceptibility of scientific endeavor, 143
- tribal nature of science, 24
- fudge factors, 136
- fudging data, 137, 165–166
- funding, 127–134
  - duration of, 131–132
  - of fraud perpetrators, 147–148
  - of human genome sequencing, 218–219
  - by lottery, 133–134
  - National Institutes of Health (NIH)
    - grants, 43, 49, 55, 58, 93, 115, 127, 128, 129–134, 147, 219–220
  - people-based, 132
  - publication influence on, 108
  - by U.S. government for research in life sciences, 128
- G**
- Galileo, 52
- Gallo, Bob, 52, 72, 189–190
- Garfield, Eugene, 93–94, 104–105
- gel electrophoresis, 213, 223, 274
- gene
  - colinearity with protein product, 200
  - concept of, 10
  - imprinted, 251–252
  - inactivation of, 258
  - interrupted, 193, 201–203
  - Mendel and concept of, 164, 166
  - number of, 221, 222, 228, 228–229
  - patents for, 47, 48, 49–50
  - physical basis, 166–170
  - size, 167
  - split, 130, 201–202, 277
  - synthesis, 57, 59
  - term introduced, 166
- gene editing, 10, 47, 155, 176, 233–242. *See also* CRISPR
- gene expression
  - definition, 274
  - epigenetic control of, 248
  - resetting the state of, 259
- Genentech, 34, 54–60
  - management style, 58
  - South San Francisco campus, 56, 59
- gene targeting, 130
- The Gene* (Mukherjee), 250
- gene therapy, 233
- genetic code, 176, 184–185, 199–200, 274
- genetic engineering. *See also* recombinant DNA
  - concerns over, 155
  - ethical considerations, 150–151
- genetics
  - DNA structure, 171–181
  - history, 163–170
  - Mendel, 163–166
  - Schrödinger, 167
- genome, 221–231
  - amount of DNA in, 222
  - definition, 274
- genome sequences
  - correlations among, 37
  - human and chimpanzee compared, 229–230
  - human and Neanderthal compared, 230
  - as tool, 32
- genome sequencing
  - cost and speed of, 224–226, 225
  - human genome sequencing, 215–219, 221–231
- genomics, 36
- Genomic Sciences, 47
- Geological Society of London, 69
- germline cells, 274
- germline editing, 149, 155–157
- Gilbert, Wally, 57, 59, 79, 216–219, 223
- Gonda, Matthew, 26
- Goodfield, June, 39
- Google Flu Trends, 32
- Gordon Research Conference on Nucleic Acids, 150–151
- Gosling, Raymond, 173, 174, 176, 180
- grant applications
  - gaming the system, 130
  - proportion funded, 129, 130, 133
  - rejection, 133
  - review of, 93, 129–130, 132–133
  - writing, 128–130, 133
- grants
  - duration of, 131
  - funding by lottery, 133–134
  - National Institutes of Health (NIH), 43, 49, 55, 58, 93, 115, 127, 128, 129–134, 147, 219–220
  - university's monetary share of, 131

- Grassi, Orazio, 52  
Greally, John, 250  
Green, Howard, 34–35  
green open access, 115–117  
Gross, Ludwik, 189  
growth factors, 33  
*The Guardian* newspaper, 118  
Gurdon, John, 257–259
- H**
- Haemophilus influenzae*, 226  
hammerhead ribozyme, 198  
hard sciences, 8  
HARKing, 66  
Harvard, 223, 239, 250  
Hassabis, Demis, 20–21  
Healy, Bernadine, 46, 157  
He Jiankui, 156  
heredity, 163–164, 166–167, 169, 185, 193, 243–245  
  dogmas of, 196  
  environmental effects on, 205  
Hershey, Alfred, 169  
Heryneker, Herbert, 34  
heterogeneous RNA (hnRNA), 202–203, 275  
HHGE (human heritable germline editing), 157  
HHMI (Howard Hughes Medical Institute), 115, 118, 132, 181, 274  
Higgs, Peter, 87, 108  
Higgs boson, 34, 108, 226  
Hinuma, Yorio, 190  
histones, 249, 253  
history  
  DNA structure, 171–181  
  doctrines, 193–206  
  dogma, 183–192  
  Gregor Mendel, 163–166, 165, 169–170  
HIV, 52, 72, 156, 158, 190, 190–191  
hnRNA (heterogeneous RNA), 202–203, 275  
Holmes, Sherlock, 193, 198  
Holton, Gerald, 135  
Hooke, Robert, 52, 96  
Horvath, Philippe, 236–237  
Howard Hughes Medical Institute (HHMI), 115, 118, 132, 181, 274  
Hoyle, Fred, 266  
HTLV (human T-cell leukemia virus), 190, 275  
HUGO (Human Genome Organization), 223, 275  
human cloning, 154  
human embryo research, 154  
Human Genome Project, 221–223  
  accuracy, 228  
  Bermuda Principles, 33, 84, 85  
  big science approach, 227, 229  
  Celera competition with, 227–228, 231  
  Craig Venter, 46, 226–227  
  data mining, 32–33, 36  
  Eric Lander, 156, 227  
  funding, 16  
  Jim Watson, 209, 222–223  
  open access, 33, 84  
  path to, 216–219  
  peer review, 132  
  reaction to patenting, 46, 48  
  reporting on, 153  
Human Genome Sciences, 48  
human genome sequence, 47, 84–85  
human genome sequencing, 215–219, 221–231. *See also* Human Genome Project  
  annotation, 228  
  by Celera, 227–228, 231  
  cost, 224–226, 225  
  draft sequencings, 228  
human heritable germline editing (HHGE), 157  
humanities  
  citation frequency of papers, 92  
  difference between science and, 6–8, 25  
human T-cell leukemia virus (HTLV), 190, 275  
Hunkapiller, Michael, 47  
hybridomas, 43, 44, 275  
hypothesis  
  falsifying, 16, 23, 67, 183  
  Karl Popper on, 193  
  Medawar genesis of, 65  
  testing, 3, 5, 15–16, 22, 66–67, 179  
hypothesis-driven science, 16, 18, 28–29, 32, 36, 77, 93, 177, 241, 258, 265, 271  
hypothesis-obsessed science, 84  
hypothesizing after results known (HARKing), 66
- I**
- IEGs (Information Exchange Groups), 111  
immune system, bacterial, 235, 238, 242  
impact factor  
  *Cell, Nature, and Science* journals, 94, 114



- correlation to retraction index, 141
- defined, 94
- of different publication sources, 99–100, 114
- eLife*, 118
- number of citations compared to, 96
- use to assess tenure candidates, 108
- Imperial College, 131
- imprinting, 251–254
- incomprehension of science, 6–7
- Incyte, 48
- independent variables, 243
- individual contributions, emphasis on, 16, 28, 34
- induced pluripotent stem (iPS) cells, 261–262, 275
- induction, 15, 22
- industry, academia's relationship with, 53–62
- influenza, 32
- Information Exchange Groups (IEGs), 111
- Ingelfinger, Franz, 102
- Ingelfinger rule, 102
- Ingram, Vernon, 211
- ingredients, unique, 83
- inheritance
  - theory of, 243, 247
  - transgenerational, 255
- innovation, dependence on small-scale science, 27
- Institute for Scientific Information (ISI), 93, 94, 104
  - Atlas of Science, 104
- Institut Pasteur, 190
- insulin, 42, 54–55, 57–60, 79, 223
- interdisciplinary approach, 181
- interferon, 45, 60
- International Human Genome Sequencing Consortium, 227
- intron, 51, 201, 203, 275
- intuition, 18–19
- intuitive approximation, 22
- iPS (induced pluripotent stem) cells, 261–262, 275
- Ishino, Toshimuzi, 234
- Itakura, Keiichi, 56–57
- IVF (in vitro fertilization), 154, 155, 157, 260
- J**
  - Jacob, François, 66, 149
  - Jansen, Ruud, 234–235
  - Jarrett, William, 189
  - Jeffreys, Alec, 214–215
  - Jinek, Martin, 239
  - Johanson, Donald, 52
  - John Innes Centre, 248
  - Johns Hopkins University, 213
  - Journal of Molecular Evolution*, 235
  - Journal of Negative Results in Biomedicine*, 66
  - journals. *See* scientific journals
- K**
  - karyotype, 217, 275
  - Kawakami, Thomas, 189
  - Kelvin, Lord, 205
  - Kendrew, John, 106, 172
  - King, Mary-Claire, 49
  - King's College, London, 171–172, 177–178
  - knockout mice, 130
  - Köhler, Georges, 43–44
  - Koprowski, Hilary, 45
  - Koshland, Dan, 138–139
  - Kuhn, Thomas, 191
  - Kurzweil, Ray, 9
  - Kyoto University, 261
- L**
  - laboratory, running of, 129
  - laboratory notebooks, as property of institution, 136
  - Lamarckism, 245, 255–256
  - Lancet*, 94, 98, 100
  - Lander, Eric, 149, 156–157, 227, 241–242
  - Latour, Bruno, 23
  - Leakey, Richard, 52
  - Leeds University, 174
  - Leibniz, Gottfried Wilhelm, 52
  - leukemia, 189
  - Levan, Albert, 210
  - Levene, Phoebus, 168, 171
  - Levi-Montalcini, Rita, 136
  - Lévi-Strauss, Claude, 3
  - licensing, 39, 43, 53, 55, 58, 85
  - Lilly, 57
  - linkage, 212, 275
  - linkage map, 211, 211–213, 215
  - The Logic of Scientific Discovery* (Popper), 15
  - luck, 166, 170
  - Luria, Alexander, 136
  - Lyon, Mary, 250
  - Lysenko, Trofim, 243, 245–247, 256
  - Lysenkoism, 245

## M

- mad cow disease, 194
  - Maddox, John, 88, 98
  - Mallory, George, 32
  - mapping, 209–219
    - linkage map, 211, 211–213, 215
    - physical map, 213, 215, 217
    - with restriction enzymes, 212–214
  - Marraffini, Luciano, 236, 239
  - Materials and Methods, 68, 69, 88–89, 89
  - Maxam–Gilbert sequencing, 224
  - Max Planck Society, 118
  - Maxwell, Robert, 90
  - Mayr, Ernst, 268
  - McClintock, Barbara, 253
  - McKusick, Victor, 221
  - Medawar, Peter, 15, 65–66
  - MEDLINE database, 93
  - medRxiv, 111
  - Memorial Sloan Kettering Cancer Center, 249
  - Mendel, Gregor, 135, 163–166, 165, 169–170, 271
    - data accuracy, 165–166
    - garden in Brno, 165
    - rediscovery of work, 163, 166
  - Merck, 48
  - Merton, Robert, 4–5
  - Mertz, Janet, 149–150
  - Meselson–Stahl experiment, 179
  - messenger RNA (mRNA), 201–203, 275
  - metabolomics, 36, 275
  - methodology, poor understanding by nonscientists, 5–6
  - methylation, 37, 224, 249, 251–254, 256, 275
  - methylation analysis, genome-wide, 37
  - methylcytosine, 251–252
  - mice, epigenetics in, 253–254, 254
  - Michelson, Albert, 205–206
  - Michelson–Morley experiment, 205
  - Millikan, Robert, 135
  - Milstein, César, 43–45
  - minisatellite, 213–214, 275
  - misconduct, scientific, 136–137
  - MIT, 151–152, 156, 186, 201, 212, 216, 241
  - Mojica, Francisco, 101, 233–235, 238, 242
  - molecular biology
    - Central Dogma, 183–186, 184, 185, 191
    - definition, 181
    - discoveries in, 265–266, 266
    - first use of term, 175
    - Gunther Stent review, 204–205
    - historical phases of, 205
    - interdisciplinary approach to questions, 181
    - limits on research in, 149
    - physics and chemistry compared to, 8
    - transition, 10
  - monoclonal antibodies, 43–45, 44
  - Monod, Jacques, 66, 248, 265
  - Montagnier, Luc, 52, 72, 190–191
  - Monty Python, 257, 261
  - Moore's Law, 9
  - MRC Laboratory of Molecular Biology, 43–45, 72, 106, 172–173, 173, 175, 181
  - mRNA (messenger RNA), 201–203, 275
  - Mukherjee, Siddhartha, 250
  - Müller, Ulrich, 19
  - Mullis, Kary, 54
  - murine leukemia virus, 189
  - Murrow, Edward, 39
  - mutation, 164, 167, 211, 213, 245, 268
  - myeloma, 43, 44, 45, 275
  - Myriad Genetics, 49–50
- ## N
- Nathans, Dan, 213
  - National Academy of Sciences, 95–96, 150–151, 157
  - National Cancer Institute, 189
  - National Human Genome Research Institute (NHGRI), 36
  - National Institute of Allergy and Infectious Diseases (NIAID), 157
  - National Institute of Neurological Diseases and Stroke (NINDS), 46
  - National Institutes of Health (NIH)
    - citation of work funded by, 93
    - cost of managing grant applications, 129
    - definition, 276
    - directors, 46, 47, 110, 133, 157–158, 222
    - duration of grants, 131
    - e-BioMed, 110, 113
    - gain-of-function work in Wuhan, funding, 154
    - grants, 43, 49, 55, 58, 93, 115, 127, 128, 129–134, 147, 219–220

- human embryo research, 154
- human genome sequencing, 218–219, 226
- Information Exchange Groups (IEGs), 111
- open access, 115
- patenting DNA sequences, 46–47, 49
- proportion of grant applications funded, 129
- recombinant DNA experiments, 151, 157
- R01 grant, 132, 218–219
- National Research Council, 136
- National Research Development Corporation (NRDC), 44–45
- Nature*
  - acceptance rate, 118
  - advertisements in, 88, 89
  - authors, average number of, 180
  - as brand, 99
  - CRISPR paper, rejection of, 235
  - criticism of, 118
  - editorial decision process, 96
  - expedited papers, 172
  - external peer review, 70
  - germline editing letter, 156
  - in hierarchy of scientific journals, 91, 94–96, 97
  - impact factor, 94, 114
  - influence of, 114
  - interferon paper, 45
  - monoclonal antibody paper, 43
  - multiple journals, 98
  - objection to Information Exchange Groups (IEGs), 111
  - paywalls, 112
  - purchase by Springer-Verlag, 98
  - refusal of Montagnier paper, 72
  - Reproducibility Project, 80
  - reverse transcription papers, 186
  - Springer Nature, 77, 100, 120
  - Watson–Crick paper (1953), 177, 177
- ncRNA, 275
- Neanderthal DNA, 37, 230, 321
- negative results, publication of, 66–67, 83
- New England Journal of Medicine*, 33, 102–103, 189
  - in hierarchy of journals, 94
  - income, 112–113
  - objection to e-BioMed, 113
- Newton, Isaac, 52, 136
- Newton effect, 96–97
- next-generation sequencing, 224, 276
- NHGRI (National Human Genome Research Institute), 36
- NIAID (National Institute of Allergy and Infectious Diseases), 157
- NIH. *See* National Institutes of Health (NIH)
- NINDS (National Institute of Neurological Diseases and Stroke), 46
- Nobel, Alfred, 52
- Nobel Prize, 105–108. *See also specific recipients*
  - $\alpha$ -helix in protein structure, 172
  - apportioning credit, 178–179
  - control of gene expression, 66, 248
  - CRISPR, 10, 239
  - DNA sequencing, 216
  - DNA structure discovery, 178
  - electron charge, 135
  - for industrial research, 54
  - iPS cells, 261
  - monoclonal antibodies, 44
  - nuclear transfer, 257
  - prior discovery, 194, 196–197
  - protein folding, 196
  - restriction enzymes, 213
  - ribozyme discovery, 198, 200
  - senior authors, 178
  - sequencing Neanderthal DNA, 230
  - simultaneous or related discoveries, recognition of, 52
  - splicing and interrupted genes, 201
- Northwestern University, 236
- NRDC (National Research Development Corporation), 44–45
- nuclear transfer, 155, 157, 257–261
- nucleosome, 73, 276
- nucleotides, 168, 276
- O**
  - objective of science, 29
  - objectivity, 7
  - obsession in scientists, 61–62
  - Office of Research Integrity (ORI), 147–148
  - Office of Scientific Integrity, 147
  - oil drop experiment, 135

## 322 INDEX

- omics, 36–37, 267, 276
- online journals
  - citations in, 96
  - speed of publication, 120
  - supplemental material, links to, 120
- online publication, 109–124
  - peer review, 110–111, 113, 118–120, 124
  - supplemental information, inclusion of, 120, 123
- online publishing
  - gatekeeper function, 121–122
  - speed of publication, 103
- open access, 113, 115–120, 122–123
- open data, 33–34
- ORI (Office of Research Integrity), 147–148
- Ortega effect, 96–97
- Ortega y Gasset, José, 96–97
- oversampling, 226–227
  
- P**
- Pääbo, Svante, 230–231
- Painter, Theophilus, 210
- palindrome, 252
- Panetta, Leon, 158
- panspermia, directed, 266
- paper, scientific. *See* scientific paper
- paradigm shift, 191, 193, 197, 202, 219
- patents, 39–52
  - adrenaline, 40, 53–54
  - authorship, 56
  - BRCA1* and *BRCA2*, 49–50
  - cDNA, 50, 51
  - challenges to, 49
  - CRISPR, 47, 233, 236, 241
  - DNA sequences, 40, 45–51, 48, 51
  - effect on science, 50–51
  - exclusion of products of nature, 40
  - gene synthesis, 59
  - lawsuits concerning, 60–61
    - as legitimate objective in academic research, 62
  - licensing, 39, 43, 55, 58
  - on living organisms, 40–41, 45
  - monoclonal antibodies, 43–45
  - novelty of invention, 39
  - Pseudomonas putida*, 40–41
  - recombinant DNA, 42–43, 45, 55
  - Supreme Court rulings, 41
  - timing of application filing, 42, 44–45, 51
  - usefulness criterion, 39, 46
- Pauli, Wolfgang, 79
- Pauling, Linus, 172, 175
- paywalls, 112
- PCR (polymerase chain reaction), 54
- PDB, 86, 276
- PDGF, 33
- peer review
  - drug companies, 103
  - fraud detection, 141
  - of grants, 93, 132–133
  - online publication, 110–111, 113, 118–120, 124
  - of papers, 4, 68–74, 86, 95
  - PLoS*, 113
  - quality control by, 9
  - retractions, 139
  - signed reviews, 113
  - spectrum of rigor, 119
- penicillin, discovery, 45
- Pennica, Dianne, 72
- Pergamon Press, 90
- Perkins, Thomas, 55
- personal communication, 111
- Perutz, Max, 106, 172
- PhD candidate, 16, 61, 127
- philosophers of science, 22–23
- Philosophical Transactions*, 89
- photograph 51, 173–175, 174
- Physical Review*, 69
- physics
  - arXiv system, 110–111
  - big data/big science, 9, 18
  - biology compared, 8–9, 265, 266, 267–271
  - CERN particle accelerator, 226
  - discoveries in, 265, 266
  - disdain for other fields of science, 181
  - emergence in, 269
  - experimental science, 8
  - gene behavior, 167
  - number of authors on scientific papers, 34, 35
  - partnerships between academia and private companies, 53
  - quantum mechanics, 268, 270–271
  - reductionism, 267–271
- P.I. (principal investigator), 128, 131, 276
- plagiarism, 137, 145

- Planck, Max, 127, 271  
Plan S, 115, 117  
plants, response to temperature by,  
245–248, 247  
plasmid, 42, 150–151, 276  
*PLoS* (Public Library of Science), 99–100,  
113–115, 118, 145  
*PLoS Biology*, 113–114  
*PLoS Medicine*, 113–114  
pluripotent stem cells, 257, 260–262, 276  
politics, 98, 149–159, 182, 257  
Pollack, Bob, 150  
Polyani, Michael, 191  
polymerase chain reaction (PCR), 54  
Pons, Stanley, 82  
Popper, Karl, 15, 23, 31, 193, 266  
Porton Down facility, 80  
postdoctoral fellowship, 16, 58, 61, 127, 276  
postmodernism, 24  
preclinical studies, reproducibility of, 81  
predatory journals, 119–120  
predatory pricing  
by drug companies, 50  
by large commercial publishers, 114  
prematurity, 164, 178  
preprints, 110–111, 119–122, 276  
press  
COVID misinformation, 153  
inadequacy of reporting on science, 153  
releasing information to, 101–104  
principal investigator, 128, 131, 276  
priority  
CRISPR, 233, 241  
definition, 276  
establishing, 104  
online publication, 121  
online thread, 123  
patents, 39, 49, 51–52  
publication order, 187  
rush to obtain, 81  
scientific papers, 69, 71  
*Proceedings of the National Academy of  
Sciences (PNAS)*, 88, 91, 95, 187, 201,  
235, 237, 253  
protein  
infectious, 193–197, 195, 199–200, 267  
sequencing, 223  
protein structure, 19–21, 20  
alternative structures, 194–195, 195  
cell environment, effect of, 195  
databases, 85–86  
folding, 195–196  
proteome, 21  
proteomics, 36  
PrP, 194–195, 195, 276  
Prusiner, Stanley, 193–194  
*Pseudomonas putida*, 40–41  
pseudoscience, 5, 244–245, 266  
psychology, reproducibility problem  
in, 82  
Ptashne, Mark, 249–250  
publication. *See also* scientific paper  
author payments for, 116–118  
conflict of interest, 77  
double, 102  
electronic, 109–124  
filters en route to publication and  
publicity, 71  
of negative results, 66–67, 83  
number of, 87–88, 88  
online, 76, 109–124  
order of papers in, 187  
by press conference, 104  
of retraction, 84  
speed of, 88–89, 91, 103, 107, 120  
supplemental data, 76  
publishing  
biotech's patent and publish model, 58,  
60  
commercial, 90  
groups of journals, 98–99, 99  
large commercial publishers, 97–101,  
110, 112, 114–115, 121, 123  
predatory pricing, 114  
publish or perish, 87–108  
signal:noise ratio in scientific literature,  
91, 94, 101  
by societies, 90, 99, 111  
timeline of scientific, 112  
by university presses, 90, 99  
PubMed Central, 111–112  
PubMed database, 87, 92, 111, 112, 115,  
138, 276  
pure research/science, 53, 58, 60
- Q**  
quantum mechanics, 268, 270–271  
question-driven science, 16–17, 31, 204

## R

recombinant DNA. *See also* biotechnology  
cloning DNA, 40–42, 41, 149–150  
definition, 277  
history of, 149–154  
insulin produced from, 55  
NIH, 157  
patents, 42–43, 45, 55  
public concern over, 151–154  
rules concerning research, 59, 79–80, 151–153  
recombination frequency, 212–213  
reductionism, 11, 205, 244, 265–272  
*Reflections on the Decline of Science in England* (Babbage), 136  
regeneration, 257–259, 259  
Reimers, Niels, 42–43  
relativism, 92  
Relman, Arnold, 113  
Rennie, Drummond, 27  
reproducibility, 79–86  
discrepancies, 144, 147  
incentive for, 81  
patent condition compared, 40  
of preclinical studies, 81  
problems with, 81–83  
of published work, 4, 9  
retractions due to failure, 138  
study on, 80–81  
unifying concept in science, 79  
unique ingredients, use of, 83  
reproducibility crisis, 82  
Reproducibility Project, 80–81  
research article/paper. *See* scientific paper  
research parasites, 34  
restriction enzyme, 212–214, 219, 233, 235–236, 277  
retraction  
as blemish on record, 84  
fraud, 138–147, 140  
mass, 100  
number of authors per paper, decline with, 139, 140  
Retraction Watch database, 138–139  
retrovirus, 187–191, 190, 277  
reverse transcription, 185, 187, 193, 202–203, 277  
reward system of science, 52, 67, 81  
RFLPs (restriction fragment length polymorphisms), 213, 215

ribozymes, 198, 198–200  
Riggs, Arthur, 55, 57  
RNA (ribonucleic acid), 169  
crRNA, 237  
definition, 277  
genome sequences encoding, 221–222  
guide, 237–238, 240–241  
heterogeneous RNA (hnRNA), 202–203, 275  
messenger RNA (mRNA), 201–203, 275  
ncRNA, 275  
ribozymes, 198, 198–200  
splicing, 201–204  
translation into protein, 184  
RNA interference, 233, 236, 238  
RNA sequencing (RNA-seq), 224–225, 277  
RNA virus, 185, 185, 187–188  
RNA World Hypothesis, 199  
Roberts, Rich, 201–203  
Rockefeller University, 188, 239  
Rous, Peyton, 188–189  
Rous sarcoma virus, 188  
Royal Society of London, 69, 89–90  
running a laboratory, 129  
Rutherford, Ernest, 34, 181

## S

Salk, Jonas, 39  
Sanger, Fred, 216, 223  
Sanger Center, 48  
Schekman, Randy, 118  
Schrödinger, Erwin, 11, 65, 167  
*Science*  
acceptance rate, 118  
Celera publication, 85  
CRISPR papers, 236, 238–239  
criticism of, 118  
Dan Koshland, 138  
editorial decision process, 96  
external peer review, 70  
germline editing letter, 156  
in hierarchy of scientific journals, 91, 94–96, 97  
impact factor, 94, 114  
influence of, 114  
objection to Information Exchange Groups (IEGs), 111  
Reproducibility Project, 80  
somatostatin paper, 56  
speed of publication, 88  
*Science, the Endless Frontier* (Bush), 159

- Science Citation Index (SCI), 93
- Scientific attitude, 5, 8–9, 23, 29, 78, 200
- scientific journals
  - barrier to starting, 118
  - as brands, 98–99
  - charges for article publication, 116–118
  - gatekeeper role of, 121–122
  - groups, 98–99, 99
  - hierarchy, 91, 94–96, 97, 105
  - impact factor, 94, 99–100, 114, 118
  - number of, 87, 96, 99–101
  - online, 96
  - origin and history, 89–91, 90
  - predatory, 119–120
  - price, 90, 100–101, 116, 119
  - rejection of CRISPR papers, 235, 238
  - reviews and commentaries, 107
  - subscriptions, 95, 110, 113–118
- scientific method, 15, 17, 22–23, 177
- scientific paper
  - accuracy, 138–139
  - artificial intelligence (AI) examination of
    - submitted, 145
  - assessment of, 17
  - authorship, 75–76
  - biotech industry, 58–60
  - changes after acceptance, 71
  - citations, 92–94
  - competition for “hot” papers, 91
  - criticism, 70, 72–74, 76
  - database as primary source, 85–86
  - disruptive papers, 27
  - expedited, 172
  - filters in route to publication and
    - publicity, 71
  - format, 68, 69
  - history, 89–90, 90
  - importance measured by citations, 93–94
  - as key unit of science, 4
  - methods papers, 93
  - myth of, 65–78, 69
  - number of authors, 34, 35, 75, 78, 87–88, 88, 139, 140, 180
  - preprints, 110–111, 119–122
  - priority, 69, 71
  - in PubMed database, 87, 92
  - rejection of, 75–76, 89, 91–92, 96, 120–121, 141, 143, 146
  - reproducibility of experiments reported, 80–81
  - responsibility of authors, 26–27
  - retraction, 83–84, 100, 138–147, 140
  - review of, 4, 68–74, 86, 95, 120, 122, 141
  - supplemental data, 76
  - threads as alternative format, 123–124
  - transition to submitting data to database, 86
  - as unit of assessment, 109
  - unpublished data cited in, 76
  - written in first person, 68
  - written in third person, 67
- scientist
  - career, 127–129
  - illiteracy, 6–7
  - mindset, 9, 11, 15, 25
  - obsession, 52, 61–62
  - origin of term, 22–23
  - specialization, 5, 65, 78
  - training, 128, 132
- scrapie, 194, 197
- Secher, David, 45
- Second Law of Thermodynamics, 6, 92
- self-correcting mechanism of science
  - big data/big science, 33, 231
  - database data validation, 86
  - discrepancies, 144, 147
  - fraud, response to, 144, 146–147
  - negative results, importance of, 67
  - number of human genes, 229
  - reproducibility and, 4, 9, 80, 82
  - self-policing, 144, 147
  - triumph of data, 5
  - value system of science, 28
- self-policing mechanism of science, 144, 147
- self-verifying system, science as, 4
- Sequence Hypothesis, 183–184
- sequencing. *See* DNA sequencing; human genome sequencing
- sex chromosomes, 210–211, 277
- Sharp, Phil, 201–202
- short regularly spaced repeats (SRSRs), 234
- shotgun cloning, 226–227, 277
- shotgun sequencing, 226–227
- sickle cell anemia, 211
- signal:noise ratio in scientific literature, 91, 94, 101, 119, 121, 255
- Šikšnys, Virginijus, 237–239
- simian sarcoma virus, 33
- Singularity, 9, 21
- Sinsheimer, Robert, 215

- skepticism  
  data viewed with, 145  
  dogma and, 192  
  organized, 5  
  of prions, 197  
  protection against falling into dogma, 204  
  of reverse transcription, 203
- Skolnick, Mark, 49
- sloppiness, 135, 137, 144, 148
- Smith, Dave, 217–218
- Smith, Ham, 213
- Snow, C.P., 3, 6–7, 25, 257
- social sciences  
  citation frequency of papers, 92  
  controls, difficulty with, 5, 8  
  epigenetics, 244  
  reproducibility problem in, 82
- societies, publishing by, 90, 99, 111
- sociology, skepticism about, 23–24
- soft sciences, 8
- somatostatin, 55–57
- Sontheimer, Erik, 236, 239
- Southern, Ed, 93
- specialization, 5, 25–26, 180, 209
- Spiegelman, Sol, 186–187
- splicing, 201–204, 277
- split gene, 130, 201–202, 277
- Springer, 100, 112–113
- Springer Nature, 77, 100, 120
- Springer-Verlag, 98
- SRSRs (short regularly spaced repeats), 234
- Stanford University, 149
- statistical fallacy, 82–83
- stem cells, 257–262, 258  
  embryonic, 257, 259–261  
  pluripotent, 257, 260–262, 276
- Stent, Gunther, 204–206
- The Structure of Scientific Revolution*  
  (Kuhn), 191
- subscription, 95, 110, 113–118
- Sulston, John, 31, 47–48, 85, 228–229
- Supreme Court rulings, 41
- Suram, Azim, 251
- SV40, 150, 213, 277
- Swanson, Bob, 55, 57
- symposium proceedings, 102
- Temin, Howard, 185–187, 202
- Tetrahymena*, 198–199
- tetranucleotide theory, 168, 175
- theory  
  emergence of new, 192  
  experiment relationship with, 200  
  science advancement and, 191  
  threat of becoming dogma, 204
- Thomson, Jamie, 260
- threads, 123–124
- thyroxine, 54
- T4 page, 169
- training of scientists, 127–129, 277
- transcription, 184–187, 277
- transcription factors, 261
- transcrRNA (*trans*-encoded small RNA),  
  237, 239
- translation, 184, 277
- transparency, 119, 121
- tribal, science as, 24
- trimming, 136
- truth, objective, 8
- The Two Cultures* (Snow), 6, 25
- U**
- Umeå, 237, 239
- uncertainty, 18, 267, 271
- universalism, 4
- University of Alicante, 234
- University of Amsterdam, 214
- University of Berkeley, 237–238
- University of California, Los Angeles  
  (UCLA), 155–156
- University of California, San Francisco  
  (UCSF), 114, 193
- University of California, Santa Cruz  
  (UCSC), 215
- University of Colorado, 198
- University of Edinburgh, 93, 108
- University of Leicester, 214
- University of London, 131
- University of Oxford, 257
- University of Utah, 49, 82, 130
- University of Wisconsin, 185, 260
- university presses, 90, 99
- unpublished data, 76, 111, 123, 140, 173, 178
- V**
- value system of science, 23–24  
  commercial attitudes, 61  
  features of, 4–5



in grant funding, 134  
looking for fraud, 145  
patents, 39  
paying for information, 47  
self-correction, 28  
van der Oost, John, 237  
Varmus, Harold, 47, 133, 135, 154, 157, 190  
Velazquez, Jose Luis Perez, 131  
Venter, Craig, 46–47, 219, 226–227  
venture capitalists, 55  
verification, 21, 28, 32  
vernalization, 245–246, 247  
Vickers, Tony, 43  
Villa-Komaroff, Lydia, 80  
Vilnius University, 237–238  
virus  
  bacteriophage, 167–169, 169, 204, 212, 237  
  cancer-associated, 185, 188–191  
  discovery of split genes in, 130  
  retrovirus, 187–191, 190  
  RNA, 185, 185, 187–188  
vitamin B12, 54  
Voltaire, 78

## W

Waddington, Conrad, 248, 249  
Walter, Peter, 114  
Washington University, 48  
Watson, Jim  
  bacteriophage DNA, 167  
  Cold Spring Harbor Laboratory, 189, 201, 222–223  
  DNA structure, 171–173, 175, 175–178, 180, 209  
  *The Double Helix*, 67, 172–173  
  genome sequencing, 209, 219, 221

Human Genome Project, 209, 222–223  
  on human improvement, 149  
  on insider information, 70  
  on NIH RO1 grants, 219  
  Nobel Prize, 106, 178  
Weinberg, Steve, 9, 268–269  
Wellcome Trust, 115, 118  
Westfall, Richard, 136  
*What Is Life?* (Schrödinger), 11, 167  
*What Mad Pursuit* (Crick), 173–174  
Whewell, William, 22  
whistleblower, 147  
Whitehead Institute, 156  
Wiedenhaupt, Blake, 239  
Wilkins, Maurice, 67, 171–173, 176–178, 180  
Wistar Institute, 45  
Wyngaarden, James, 222

## X

X chromosome, 210–211, 250–251, 277  
*Xenopus laevis*, 258, 259  
X-inactivation, 250–251, 277  
X-ray diffraction, 171, 174, 177, 180

## Y

Yale, 198  
Yamamoto, Keith, 114  
Yamanaka, Shinya, 261  
Yeats, William Butler, 134  
yogurt, 235–236, 241

## Z

Zhang, Feng, 156, 239–240  
Zuckerman, Harriet, 105–106